The San Diego meeting includes regenerative medicine, injectables, energy devices and safety sessions.
ASDS 2026 meeting: what is happening?
The ASDS 2026 meeting begins on 5 November in San Diego, California. The American Society for Dermatologic Surgery has scheduled four days of education through 8 November. Pre-conference sessions take place on 4 November.
The programme includes cosmetic dermatology, skin cancer surgery, injectables, energy-based devices and regenerative medicine. The society also plans live demonstrations and practical workshops. This is a conference preview, not a report of new clinical results. The scientific sessions have not yet taken place at the time of this edition.
What is on the programme?
The society lists five plenary sessions, four days of continuing medical education and three cadaver-based surgical demonstrations. It also lists three live patient demonstrations and three hands-on workshops. Planned subjects include injectables, energy-based devices and surgical skills.
Regenerative medicine and international controversies appear among the featured plenary themes. These topics matter because new treatments often spread through conferences before strong long-term evidence is available. Education can improve technique, but a conference presentation does not automatically prove a treatment works.
Why the safety sessions matter
The programme includes a session focused on complications. That is important for a field where patients may seek procedures with little recovery time but still face meaningful risks. Injectables, lasers and other devices require careful patient selection and an understanding of anatomy.
The strongest teaching should explain both benefits and limits. It should also separate established methods from early ideas. Clinicians should pay attention to complication reporting, practical prevention steps and the quality of evidence behind new techniques.
What to watch over the next four days
The most useful stories will be those with clear study designs, patient numbers and safety data. The newsroom should also watch for regulatory documents and official product announcements made during the meeting. Any new device claim needs its exact model, country and authorised indication.
Meanwhile, new injectable or regenerative claims should distinguish early evidence from clinical proof. The conference offers a strong reporting opportunity. The challenge is to report what has actually been shown, rather than what a product or presentation promises.
Original source (clickable): Primary-source document
Original source date: 4 November 2026 preconference; meeting 5–8 November
This article is published by Aesthetics.news for general information and educational purposes only. It does not constitute medical advice, diagnosis or treatment, and should not replace a consultation with a qualified healthcare professional. Treatments and outcomes may vary from person to person. Readers should seek advice from an appropriately qualified professional before making decisions about their health or treatment. In a medical emergency, seek immediate medical assistance.